Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 173.4 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; crospovidone; titanium dioxide; hyprolose; colloidal anhydrous silica; macrogol 8000; lactose; monobasic sodium phosphate dihydrate; dibasic sodium phosphate; indigo carmine aluminium lake; monobasic sodium phosphate monohydrate - the treatment of osteoporosis,the treatment of glucocorticoid-induced osteoporosis,the preservation of bone-mineral density in patients on long term corticosteroid therapy

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.1387 mg - tablet, uncoated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; lactose; croscarmellose sodium; purified water; gelatin; aluminium starch octenylsuccinate; aluminium sodium silicate; sucrose; medium chain triglycerides - the treatment of osteoporosis in select patients where vitamin d supplementation is recommended.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.0693 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; lactose; microcrystalline cellulose; magnesium stearate; purified water; gelatin; aluminium starch octenylsuccinate; aluminium sodium silicate; sucrose; medium chain triglycerides - the treatment of osteoporosis in select patients where vitamin d supplementation is recommended.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - calcium carbonate, quantity: 1.25 g (equivalent: calcium, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; croscarmellose sodium; povidone; magnesium stearate; hypromellose; macrogol 8000; chlorophyllin-copper complex; titanium dioxide; carnauba wax - for the treatment of: ? osteoporosis in select patients where vitamin d and calcium supplementation is recommended,prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - colecalciferol, quantity: 0.14 mg; alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: gelatin; croscarmellose sodium; butylated hydroxytoluene; colloidal anhydrous silica; sucrose; magnesium stearate; microcrystalline cellulose; povidone; medium chain triglycerides - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.07 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; povidone; gelatin; croscarmellose sodium; medium chain triglycerides; microcrystalline cellulose; magnesium stearate; sucrose; butylated hydroxytoluene - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - risedronate sodium, quantity: 35 mg - tablet, enteric coated - excipient ingredients: polysorbate 80; stearic acid; purified talc; microcrystalline cellulose; triethyl citrate; iron oxide yellow; magnesium stearate; disodium edetate; methacrylic acid - ethyl acrylate copolymer (1:1); sodium starch glycollate type a; simethicone; colloidal anhydrous silica - treatment of osteoporosis. treatment of glucocorticoid-induced osteoporosis. preservation of bone mineral density in patients on long term corticosteroid therapy.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 40.5 mg (equivalent: risedronate sodium, qty 35 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; iron oxide red; macrogol 8000; magnesium stearate; hyprolose; lactose; titanium dioxide; hypromellose; crospovidone; iron oxide yellow - - treatment of osteoporosis. - treatment of glucocorticoid-induced osteoporosis. - preservation of bone mineral density in patients on long term corticosteroid therapy.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - risedronate sodium, quantity: 150 mg - tablet, film coated - excipient ingredients: macrogol 8000; microcrystalline cellulose; hyprolose; colloidal anhydrous silica; hypromellose; crospovidone; indigo carmine; titanium dioxide; magnesium stearate; macrogol 400 - treatment of osteoporosis. treatment of glucocorticoid-induced osteoporosis. preservation of bone mineral density in patients on long-term corticosteroid therapy.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

bafna pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 172.1 mg (equivalent: risedronate sodium, qty 150 mg) - tablet, film coated - excipient ingredients: crospovidone; colloidal anhydrous silica; microcrystalline cellulose; mannitol; magnesium stearate; titanium dioxide; hypromellose; macrogol 8000; sunset yellow fcf aluminium lake; polydextrose; macrogol 400; indigo carmine aluminium lake - ? treatment of osteoporosis.,? treatment of glucocorticoid-induced osteoporosis.,? preservation of bone mineral density in patients on long term corticosteroid therapy.